Bring BPaL2Me Trial Comparing Nurse-Led Rifampicin-Resistant Tuberculosis Treatment in Primary Care Clinics to Physician-Led Hospital-Based Outpatient Treatment A Cluster Randomized Non-Inferiority Study
Led by Johns Hopkins University · Updated on 2026-10-26
2944
Participants Needed
5
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating nurse-led treatment for rifampicin-resistant tuberculosis RR-TB in primary care clinics compared to standard physician-led treatment at district hospitals in South Africa. This multi-site, cluster randomized trial aims to assess treatment outcomes, safety, and patient costs over five years. The study also explores how this approach affects HIV co-infected patients and addresses the high costs and access barriers associated with hospital-based care.
Participants will receive RR-TB treatment either through nurses available once or twice weekly at primary care clinics or through physicians at hospital outpatient sites. Nurse availability will rotate between clinics to mirror physician duties. The trial will compare the two approaches for treatment success, safety events, and catastrophic costs exceeding 20% of household income. Secondary goals include evaluating timing for treatment initiation, symptom resolution, provider adherence, and cost-effectiveness.
During the study, participants will be closely monitored through laboratory tests, clinical assessments, and cost tracking over 12 months. Key outcomes include treatment success at six months, severe adverse events within a year, and patient cost burdens. The study involves regular evaluations of dosing adjustments and HIV-related treatment milestones. Participation spans from initial diagnosis through a year of follow-up, with blinded analysis and safety reviews to ensure data integrity.
Primary Care Clinics must be within selected hospital catchment areas in KwaZulu-Natal, Gauteng, or Eastern Cape provinces
Provincial TB program managers and hospital leadership must agree to participate
Nurse managers at participating primary care clinics must agree to participate
Clinics must diagnose 10 or more RR-TB patients per year
Clinics must have access to labs, X-ray, and ECG equipment
Adults aged 18 years and older with a new RR-TB diagnosis
Participants must be willing and able to provide informed consent in Zulu, Xhosa, Afrikaans, or English
You will not qualify if you...
Clinical presentation requiring hospital admission (e.g., severe weakness, confusion, severe mental illness, low blood pressure, severe shortness of breath, temperature over 39.0°C)
Hemoglobin less than 8 mg/dL or liver disease with ALT over 120 U/L
Prolonged QTc interval greater than 470 ms confirmed by two or more ECGs
Tachycardia with heart rate over 140 bpm confirmed after 5 minutes rest
Pregnancy
Evidence of extrapulmonary tuberculosis
Enrollment in another clinical trial altering BPaL-L regimen, duration, or symptom management
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 12 months
Participants receive rifampicin-resistant tuberculosis treatment either from nurses at primary care clinics or physicians at hospital outpatient sites. Nurses rotate between clinics and are available once or twice weekly. Physicians provide care at hospital-based outpatient clinics.
Visits once or twice weekly depending on site
Follow-up
Duration - 12 months
Participants are monitored for treatment outcomes, safety, and costs over 12 months with regular clinical evaluations and laboratory tests.
Regular monitoring visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Task shifting and integration of HIV care into primary care in South Africa: the development and content of the streamlining tasks and roles to expand treatment and care for HIV (STRETCH) intervention.
Kerry E Uebel, Lara R Fairall, Dingie Hcj van Rensburg...